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ABSTRACT
BACKGROUND: Myasthenia gravis is a chronic acquired autoimmune disorder in which autoantibodies are produced
against acetylcholine receptors present on neuromuscular junction. It results in neuromuscular transmission blockage
hence muscle weakness occurs. Thymus gland is considered as having crucial role in development of these antibodies.
Screening patients for thymoma and removal of the thymus gland with surgery has an important aspect in
management of disease.
OBJECTIVE: To compare the clinical outcome of patients with myasthenia gravis treated with or without thymectomy.
MATERIAL AND METHODS: Study design: Retrospective observational comparative study.
SETTING: Department of Neurology, Mayo hospital, Lahore. Duration: patients with myasthenia gravis from 2014 to
2017.
Procedure: 40 Patients with myasthenia gravis Osserman stage from 1 to 4 treated from 2014 to 2017, irrespective
of age and gender were included. Diagnosis of myasthenia Gravis was based on positive EMG study, acetylcholine
receptor antibodies and Pyridostigmine test (as Edrophonium was not available). Records of 20 patients that
underwent thymectomy and 20 patients which were managed conservatively were obtained. Outcome in patients
having thymectomy was assessed on the basis of MGFA Post intervention status after 1year.
RESULTS: study sample (40 patients) includes 15 males and 25 females. The mean age of patients was 33 years
(range 14 to 63, SD 11.2). In thymectomy group, 7 males and 13 females (age range 16 to 53years, means age 32,
SD 10) that underwent thymectomy. With thymectomy, 14 patients improved, 6 remained unchanged while no
patients showed worsening or exacerbation of their symptoms. There were 8 males and 12 females of age 14 to 63
years that were managed without thymectomy. Of them, 2 patients improved, 6 remained unchanged, and 12 had
worsened symptoms while no patients showed exacerbated symptoms. The difference among the two groups was
statistically significant (p<0.05).
Conclusion: After thymectomy there was a substantial dose reduction in antimyasthenic treatment with minimum or
no exacerbation as compared to patients without thymectomy. So all patients of myasthenia gravis should be offered
thymectomy as a part of treatment. This conclusion is in line with guidelines for the management of myasthenia gravis.
KEY WORDS: myasthenia Gravis, thymectomy, complete remission.
INTRODUCTION
Myasthenia gravis (MG) is a chronic acquired
autoimmune disease of neuromuscular junction
leading to muscular weakness. There are large number
of molecules, including ion channels and various
proteins, present at the neuromuscular junction, which
can be targeted by autoantibodies resulting in blockage
of neuromuscular transmission.1
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Population-based studies of the epidemiology of
myasthenia gravis have been conducted for over 50
years. A clear increasing trend has been reported.
Recently, estimated prevalence is about 20 per
100,000 in United States.2 Patients with myasthenia
gravis have fluctuating fatigability in voluntary muscles
of body predominantly ocular, oropharyngeal, facial,
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respiratory and limbs muscles.3 The role of thymus
gland in pathogenesis of myasthenia gravis is
incompletely understood, but consider as major driving
factor for the production of acetylcholine receptor
autoantibodies. Mostly patients with myasthenia gravis
have thymic abnormalities, i.e >50% is thymic
hyperplasia, and 10–15% is a thymic neoplasm.4
Treatment is with pharmacological measures with or
without thymic surgery. Medication consists mainly of
acetylcholinesterase inhibitors (such as neostigmine,
pyridostigmine) which reduce the breakdown of
acetylcholine at the neuromuscular junction and hence
increase the amount of acetyl choline available to act
on the remaining post synaptic receptors. Alongside
with this symptomatic therapy, immunomodulators are
used to dumpen the autoimmune response.5
Thymectomy is one of the treatment modality to treat
MG.6 The removal of thymus gland with surgery has
been an alternative treatment modality for myasthenia
gravis since Blalock had performed a successful
thymectomy in young female with MG and thymus
cysts.7 We aimed to conduct this study to find the
beneficial role of thymectomy for myasthenia Gravis
patients in recovery from myasthenia.
We aimed to conduct this study to understand the
potential benefits of thymectomy in our myasthenia
gravis patients. We hypothesized that patients treated
with thymectomy will have better clinical outcome,
compared to the patients managed purely with
pharmacological means.

Gravis, ocular myasthenia with normal thymus having
disease less than one year, HIV patients.
Data collection: After taking approval from ethical
committee, medical record of 40 patients was
obtained. Diagnosis of myasthenia gravis was based on
positive EMG/RNS study, acetylcholine receptor
antibodies and Pyridostigmine test (as Edrophonium
was not available). Record of 20 patients that
underwent thymectomy and 20 patients that did not
get thymectomy was obtained. Then patients were
called for follow-up in OPD and clinical assessment was
be done for myasthenia Gravis. Outcome in patients
having Thymectomy assessed on the basis of MGFA
Post intervention. Complete remission of disease was
defined as patients with normal muscle strength,
without medications for myasthenia gravis for at least
1years (fig 1). Data was entered and analysed by SPSS
21. Both groups were compared for complete
remission by using chi-square test and p-value≤0.05
was considered as statistically significant
RESULTS
Study sample (total 40 patients) includes 15 males
and 25 females. The mean age was 33 years (range 14
to 63, SD 11.2). Table 1 In thymectomy group, 7 males
and 13 females (age range 16 to 53 years, Mean age
was 32, SD 10) that underwent thymectomy. With
thymectomy, 14 patients improved, 6 remained
unchanged while no patients showed worsened or
exacerbated symptoms. There were 8 males and 12
females of age 14 to 63 years that did not undergo
thymectomy. Without thymectomy, 2 patients
improved, 6 remained unchanged. The difference was
significant (p<0.05). Fig 2 In both groups, complete
stable remission was absent in all patients,
pharmacologic remission was also nil while minimal
manifestation status 3 was observed in all patients in
both group (100%). Fig 3

OBJECTIVE
To compare the clinical outcome of Myasthenia Gravis
patients treated with or without thymectomy.
MATERIAL AND METHODS
Study
design:
comparative study.

Retrospective,

observational

Setting: Department of Neurology, Mayo hospital,
Lahore.

DISCUSSION
Thymic abnormalities like Thymomas are present in
10% of patients with myasthenia gravis, and
thymectomy is mandatory.8 Mostly published literature
on thymectomy has consisted of either non-randomized
observational trials or case-control studies, mainly
relying on remission rates.9 10 The potential benefits of
thymectomy in improving clinical outcomes in
myasthenia gravis (MG)
patients without thymic
abnormalities is still under study, despite the fact that
it is used in clinical practice for more than 60 years.11
thymectomy improves various clinical parameters and
reduces the need for pharmacological treatment in
patients with myasthenia gravis. When combined with

Duration: Patients with MG treated from 2014 to
2017.
Sampling technique: Non-probability, consecutive
sampling.
Selection criteria:
Inclusion criteria: all patients with myasthenia gravis,
Osserman stage from 1 to 4 treated from 2014 to
2017, irrespective of age and gender.
Exclusion criteria: Patients with recurrent myasthenia
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standard immunosuppressive therapy, surgery gives
more benefits as compared with steroids alone.
Importantly it also decreases the requirement for
steroids or immune suppressants, hence their side
effects.12 In our study, we observed that patients in
thymectomy
group
were
improved
clinically,
pharmacological remission with minimal manifestation
(MM3). Patients in non-thymectomy group had
frequent
exacerbations
than
thymectomy
group.Regardless of MG condition, all patient should
undergo thymectomy (with or without thymoma).
Thymectomy is indicated in myasthenia gravis to
improve clinical outcomes and reduce the need for
immunosuppressive drugs in patients with myasthenia
gravis.13 According to another trial, 26.0% patients
were in complete stable remission, 35.6% patients
were without symptoms on reduced medications, and
17.8% patients had clinical improvement even further
dose reduction. Overall, 79.4% of patients benefited
with surgery, 8.2% had unchanged clinical status in
disease, and 12.3% showed worsening clinically.14
However, the complete stable remission rate (26.0%)
was less as compared to other reported series
(14%-47%).15-17 In another trial, 113 consecutive
thymectomies were done in patients with MG,
complications rate was 14%. Complete stable
remission was noticed in 21% of patients, and
significant improvement of MG in 54%, so total
beneficial rate was 75% and 14% had unchanged
status, and 11% (10 of 92) were worsened clinically.18
In another trial, 42 patients with myasthenia gravis
having thymoma were compared with 42 MG patients
without thymoma using a modified Osserman
classification. The mean Osserman grades at time of
diagnosis, 6 months, 5 and 10 years post-thymectomy
did not differ among groups. Results indicate that
thymoma should not be considered as major poor
prognostic factor for the long-term outcome of MG.19
Thymectomy exhibits satisfactory long-term clinical
benefits in patients with myasthenia gravis without
thymic abnormalities. Although presence of anti-MuSK
antibodies correlates with poor response to operation.20
Thymectomy improved clinical status over a 3-year
period in patients with myasthenia gravis without
thymic abnormalities.

Fig 1: criteria for assessment of Myasthenia Gravis
patients after thymectomy (MGFA-PIS)
Complete remission: pt. no S/S of MG for one year
and no medication
Remission CSR: no clinical weakness on examination
Pharmacological remission: same as CSR, taking
medicine but no on cholinesterase inhibitors
MM: No symptoms
examination

but

weakness

clinical

MM0: pt. did not receive MG treatment for one year
MM1: pt. is taking immunosuppression but no
cholinesterase inhibitors
MM2: pt. is taking cholinesterase inhibitors <120mg
pyridostigmine for a year
MM3: pt. is receiving both immunosuppressant and
cholinesterase inhibitor
CHANGE IN STATUS
IMPROVED: a decrease in clinical manifestations or
dose reduction in previous treatment Unchanged: no
change in clinical manifestations or dose reduction in
previous treatment
WORSE:
increase
in
manifestations or dose

pre-treatment

clinical

EXACERBATION: pt who is fulfilling criteria of CSR or
PR but showing clinical worsening
DIED: death of MG pt. either on treatment or after
thymectomy
Fig 2: Comparison of outcome in both groups (p>0.05)
Fig 2: Comparison of long term outcome in both
groups

CONCLUSION
After thymectomy there is substantial dose reduction in
anti myasthenic treatment with minimum or no
exacerbation as compared to non-thymectomy
patients. There are significant better results with
thymectomy. So all patients of myasthenia gravis
should be offered thymectomy as a part of treatment.
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Fig 3: Comparison of long-term outcome in
both groups

REFERENCES
1. Meriggioli MN, Sanders DB. Muscle autoantibodies
in myasthenia gravis: beyond diagnosis? Expert
review of clinical immunology 2012;8(5):427-38.

6. Gronseth GS, Barohn RJ. Practice parameter:
thymectomy for autoimmune myasthenia gravis
(an evidence-based review): report of the Quality
Standards Subcommittee of the American
Academy
of Neurology. Neurology 2000;55(1):7-15.

2. Phillips LH, 2nd. The epidemiology of myasthenia
gravis. Annals of the New York Academy of
Sciences 2003;998:407-12.

7. Aydin Y, Ulas AB, Mutlu V, Colak A, Eroglu A.
Thymectomy in Myasthenia Gravis. The Eurasian
Journal of Medicine 2017;49(1):48-52.

3. Meriggioli MN, Sanders DB. Autoimmune
myasthenia gravis: emerging clinical and biological
heterogeneity.
The
Lancet
Neurology
2009;8(5):475-90.

8. Drachman DB. Myasthenia gravis. The New
England
journal
of
medicine
1994;330(25):1797-810.

4. Willcox N, Leite MI, Kadota Y, Jones M, Meager A,
Subrahmanyam P, et al. Autoimmunizing
mechanisms in thymoma and thymus. Annals of
the
New
York
Academy
of
Sciences
2008;1132:163-73.

9. Sonett JR, Jaretzki A, 3rd. Thymectomy for
nonthymomatous myasthenia gravis: a critical
analysis. Annals of the New York Academy of
Sciences 2008;1132:315-28.

5. Mehndiratta MM, Pandey S, Kuntzer T.
Acetylcholinesterase inhibitor treatment for
myasthenia gravis. Cochrane Database of
Systematic Reviews 2014(10):CD006986.

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

10. Bourque PR, Warman Chardon J. A crucial first
randomized controlled trial of thymectomy in
non-thymomatous myasthenia gravis. Journal of
Thoracic Disease 2016;8(10):E1375-E8.

16

VOL. 14 (4) OCTOBER-DECEMBER 2019

8-80.
16. Bril V, Kojic J, Ilse WK, Cooper JD. Long-term
clinical outcome after transcervical thymectomy for
myasthenia gravis. The Annals of thoracic surgery
1998;65(6):1520-2.

11. Barnett C, Katzberg HD, Keshavjee S, Bril V.
Thymectomy for non-thymomatous myasthenia
gravis: a propensity score matched study.
Orphanet Journal of Rare Diseases 2014;9:214.
12. NHS. Surgery to remove the thymus gland
improves weakness for people with myasthenia
gravis.
2016 [cited 2018]; Available from:
https://discover.dc.nihr.ac.uk/content/signal-0003
10/surgery-to-remove-the-thymus-gland-improves
-weakness-for-people-with-myasthenia-gravis.

17. Huang CS, Hsu HS, Huang BS, Lee HC, Kao KP,
Hsu WH, et al. Factors influencing the outcome of
transsternal thymectomy for myasthenia gravis.
Acta
neurologica
Scandinavica
2005;112(2):108-14.
18. Budde JM, Morris CD, Gal AA, Mansour KA, Miller
JI, Jr. Predictors of outcome in thymectomy for
myasthenia gravis. The Annals of thoracic surgery
2001;72(1):197-202.

13. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo
H-C, Marx A, et al. Randomized Trial of
Thymectomy in Myasthenia Gravis. New England
Journal of Medicine 2016;375(6):511-22.

19. Bril V, Kojic J, Dhanani A. The long-term clinical
outcome of myasthenia gravis in patients with
thymoma. Neurology 1998;51(4):1198-200.

14. Kumar N, Verma AK, Mishra A, Agrawal G, Agrawal
A, Misra UK, et al. Factors predicting surgical
outcome of thymectomy in myasthenia gravis: A
16-year experience. Annals of Indian Academy of
Neurology 2011;14(4):267-71.

20. Pompeo E, Tacconi F, Massa R, Mineo D, Nahmias
S, Mineo TC. Long-term outcome of thoracoscopic
extended thymectomy for nonthymomatous
myasthenia
gravis.
European
journal
of
cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery
2009;36(1):164-9.

15. Stern LE, Nussbaum MS, Quinlan JG, Fischer JE.
Long-term evaluation of extended thymectomy
with anterior mediastinal dissection for myasthenia
gravis. Surgery 2001;130(4):774-8; discussion

Conflict of interest: Author declares no conflict of interest.
Funding disclosure: Nil
Author’s contribution:
Safia Bano; concept, data collection, data analysis, manuscript writing, manuscript review
Muhammad Ather Javed; data collection, data analysis, manuscript writing, manuscript review
Waqas Arshad; data collection, data analysis, manuscript writing, manuscript review

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

17

VOL. 14 (4) OCTOBER-DECEMBER 2019

